GlassScriptPhysician profile
Jonathan D Miller
NPI 1881908895
$32,968.67
in general payments reported to CMS, 2019-2025
33 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,848 · 2020: $1,149 · 2021: $397 · 2022: $903 · 2023: $1,491 · 2024: $2,108 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,025 · Food and Beverage: $6,872 · Travel and Lodging: $2,229 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,447.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,025.00 |
| Food and Beverage | $6,871.64 |
| Travel and Lodging | $2,228.76 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $13,761.16 | 2019-2025 | |
| Ucb, INC. | $10,215.44 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,436.10 | 2019-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $1,115.40 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $930.01 | 2019-2025 | |
| Amgen INC. | $876.54 | 2019-2025 | Krystexxa, Tavneos, Uplizna |
| Lilly USA, LLC | $790.17 | 2019-2025 | Taltz |
| Horizon Therapeutics Plc | $455.28 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $435.31 | 2019-2024 | Orencia |
| Pfizer INC. | $278.26 | 2019-2025 | |
| Glaxosmithkline, LLC. | $271.89 | 2020-2025 | Benlysta, Nucala |
| Mallinckrodt Enterprises LLC | $248.34 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $233.97 | 2022-2024 | Saphnelo |
| Ani Pharmaceuticals, INC. | $217.50 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.94 | 2019-2025 | Spevigo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $190.66 | 2022-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $167.58 | 2020-2025 | Acthar |
| Invivyd INC | $158.60 | 2024-2025 | Pemgarda |
| Genentech USA, INC. | $142.28 | 2019-2025 | Actemra, Rituxan, Gazyva |
| Alexion Pharmaceuticals, INC. | $138.94 | 2022-2025 | Strensiq |
| Sandoz INC. | $134.98 | 2023-2025 | Hyrimoz |
| Radius Health, INC. | $116.49 | 2019-2025 | Tymlos |
| Celgene Corporation | $113.43 | 2019 | |
| Scilex Pharmaceuticals INC. | $62.26 | 2024-2025 | |
| Depuy Synthes Sales INC. | $52.45 | 2024-2025 | Orthovisc, Monovisc |
| Bioventus LLC | $41.73 | 2025 | Durolane |
| Hikma Pharmaceuticals USA | $37.74 | 2019 | |
| Fresenius Kabi USA, LLC | $29.95 | 2025 | |
| Tersera Therapeutics LLC | $29.38 | 2024 | Quzyttir |
| Mylan Institutional INC. | $23.96 | 2023 | Hulio |
| Regeneron Healthcare Solutions, INC. | $22.74 | 2019 | |
| Kyowa Kirin, INC. | $18.82 | 2024 | Crysvita |
| Genzyme Corporation | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.